These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35522372)

  • 1. New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments.
    Khiali S; Entezari-Maleki T
    J Clin Pharmacol; 2022 Sep; 62(9):1055-1058. PubMed ID: 35522372
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
    Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
    Hau RK; Wright SH; Cherrington NJ
    Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants.
    Bojkova D; Stack R; Rothenburger T; Kandler JD; Ciesek S; Wass MN; Michaelis M; Cinatl J
    J Infect; 2022 Nov; 85(5):573-607. PubMed ID: 35917841
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.
    Soriano V; de-Mendoza C; Edagwa B; Treviño A; Barreiro P; Fernandez-Montero JV; Gendelman HE
    AIDS Rev; 2022 Mar; 24(1):41-49. PubMed ID: 35073629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandemic COVID-19, an update of current status and new therapeutic strategies.
    Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-generation oral antivirals against SARS-CoV-2.
    Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
    Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
    Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.
    Ferrara F; Zovi A; Trama U; Vitiello A
    Inflammopharmacology; 2022 Oct; 30(5):1927-1931. PubMed ID: 35980509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir: From Hope to Epic Fail?
    Focosi D
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.
    Pitre T; Van Alstine R; Chick G; Leung G; Mikhail D; Cusano E; Khalid F; Zeraatkar D
    CMAJ; 2022 Jul; 194(28):E969-E980. PubMed ID: 35878897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
    Dal-Ré R; Becker SL; Bottieau E; Holm S
    Lancet Infect Dis; 2022 Aug; 22(8):e231-e238. PubMed ID: 35364019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
    Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 update: NIH recommends against ivermectin.
    Med Lett Drugs Ther; 2022 Jun; 64(1652):95-96. PubMed ID: 35657909
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 updates: NIH outpatient treatment guidelines.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):32. PubMed ID: 35171899
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiviral drugs against SARS-CoV-2.
    Aiello TF; García-Vidal C; Soriano A
    Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):10-15. PubMed ID: 36285850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.